Abstract
Lactate Dehydrogenase-to-Serum Albumin Ratio (LAR), Platelet-to-Lymphocyte Ratio (PLR), and Fibrinogen-to-Albumin Ratio (FAR) are promising prognostic factors for high-grade urothelial carcinoma (HGUC) of the bladder following radical cystectomy (RC), showing substantial potential for prognostic evaluation.
Introduction
High-grade urothelial carcinoma (HGUC) of the bladder is a highly aggressive malignancy characterized by high recurrence rates and significant mortality. While radical cystectomy (RC)—the surgical removal of the bladder—is a standard treatment for localized disease, patient outcomes vary widely.
Currently, clinicians rely heavily on the TNM (Tumor, Node, Metastasis) staging system to predict prognosis. However, TNM staging alone doesn't always capture the full biological picture, such as the patient's inflammatory state or nutritional status. There is an urgent need for accessible, inexpensive, and reliable prognostic markers that can help identify high-risk patients who might benefit from more intensive follow-up or adjuvant therapies.
This study identifies three blood-based biomarkers—LAR, FAR, and PLR—as independent predictors of survival for patients with high-grade bladder cancer following surgery. By integrating these markers with traditional tumor staging into a predictive nomogram, clinicians can more accurately forecast long-term patient outcomes and potentially personalize post-operative care.
Methods
The researchers conducted a retrospective analysis of patients with HGUC who underwent radical cystectomy at a single cancer hospital between 2013 and 2021. The study utilized a clinical dataset of 180 patients from the Guangxi Medical University Cancer Hospital. The follow-up period ranged from 2 to 127 months, with an average of approximately 49 months. The patient cohort was primarily male (89.44%), with a mean age of 66 years, and included a mix of tumor stages (I through IV).
The analysis focused on three specific ratios derived from routine preoperative blood tests:
- LAR: Lactate Dehydrogenase (a marker of cell damage and metabolic activity) divided by Serum Albumin (a marker of nutrition).
- FAR: Fibrinogen (an inflammatory and coagulation marker) divided by Albumin.
- PLR: Platelets divided by Lymphocytes (reflecting the balance between pro-tumor inflammation and anti-tumor immunity).
Kaplan-Meier analysis was used to visualize survival, and Cox regression models determined independent influences on overall survival (OS). Finally, a nomogram was developed to combine these biomarkers with tumor stage for personalized survival probability.
Results and Key Insights
The study established specific clinical thresholds for the biomarkers: LAR (4.46), PLR (139.68), and FAR (0.13). Patients with ratios below these cutoffs demonstrated significantly better survival. For instance, a low LAR was associated with a 61% reduction in the risk of death (HR = 0.39).
The Power of Ratios
Individual blood counts can fluctuate, but ratios like LAR, FAR, and PLR provide a more stable "snapshot" of the interplay between the tumor's metabolic demands, the body's inflammatory response, and the patient's nutritional reserves. Systemic inflammation, captured by PLR and FAR, appears to create a "pro-tumor" environment that accelerates cancer progression. LAR emerged as a particularly strong predictor; high LDH levels often indicate a "Warburg effect" (aerobic glycolysis) within the tumor, associated with hypoxia and aggressive growth.
Synergistic Prediction and Nomogram Performance
The study’s most significant contribution is showing that these blood markers add unique predictive value beyond traditional tumor staging. A patient with a Stage II tumor and high LAR/FAR/PLR might have a worse prognosis than a Stage III patient with low ratios. The developed nomogram showed high accuracy in predicting survival at different intervals:
- 1-year OS: AUC 0.866
- 3-year OS: AUC 0.840
- 5-year OS: AUC 0.831
Decision Curve Analysis (DCA) confirmed that using the nomogram to guide clinical decisions provides a higher "net benefit" than traditional staging alone.
Discussion and Limitations
While promising, the authors acknowledge several limitations. The retrospective nature of the study and its single-center design (Guangxi Medical University Cancer Hospital) may introduce selection bias and limit generalizability. Additionally, the sample size of 180 patients is relatively small for complex predictive modeling. Finally, while the study identifies the prognostic value of these markers, it does not explore the specific molecular pathways through which they influence bladder cancer biology.
Conclusion
LAR, FAR, and PLR are accessible and effective prognostic markers for HGUC patients post-radical cystectomy. Future research should involve larger, multi-center prospective trials to confirm these findings and explore the underlying biological mechanisms.
Summary updated